Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S

doi:10.1056/nejmoa2103485

← Today's brief

Study

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan P et al. · The New England journal of medicine · Thursday, September 23, 2021

Funding Not reported

Source

Nathan P et al.. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. The New England journal of medicine. Thursday, September 23, 2021.
doi:10.1056/nejmoa2103485Read original ↗

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.